Patents Represented by Attorney, Agent or Law Firm Bonnie J. Davis
  • Patent number: 8349374
    Abstract: Noni juice and a protein-free, alcohol precipitate of Noni juice inhibited angiogenesis in in vitro human angiogenesis models. When growth medium contained Noni juice at least over the range from about 2.5% to about 33% (by volume), angiogenesis was blocked. Moreover, Noni juice and an ethanol precipitate were able to destroy a pre-existing angiogenic response as well as prevent the development of new vessels. Noni juice was effective in inhibiting the growth of angiogenic vessels from breast cancer explants. It will also be effective in treating cancers and non-cancerous diseases whose response includes an increase in angiogenesis, e.g., retinopathy of prematurity, neovascular glaucoma, diabetic retinopathy, and psoriasis. In an initial experiment, Noni juice was effective in treating lesions associated with psoriasis. The primary antiangiogenic component is believed to be a carbohydrate with a molecular weight less than about 6000 Daltons.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: January 8, 2013
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Eugene A. Woltering, Conrad A. Hornick, Amy E. Myers
  • Patent number: 8334000
    Abstract: An extract of Chinese blackberry (Rubus suavissimus) has been found to inhibit angiogenesis, and two active fractions isolated. Gallic acid was shown to be one of the active anti-angiogenic compounds by an in vitro human angiogenesis model. Aqueous extracts from other plants either known or found to have gallic acid were also found to have anti-angiogenic activity. Various derivatives of gallic acid were found to inhibit angiogenesis. The extract from Chinese blackberry also slowed the growth of a pancreatic tumor and of corneal neovascularization in rats. Extracts from pomegranate were shown to inhibit angiogenesis in fat tissue. Extracts from Rubus spp, and other plants with gallic acid, and gallic acid and its derivatives will be useful for treating various diseases associated with neovascularization, including diabetic retinopathy, psoriasis, tumors, obesity, cancer, rheumatoid arthritis, etc.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: December 18, 2012
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Frank L. Greenway, Zhijun Liu, Eugene A. Woltering
  • Patent number: 8304521
    Abstract: Pax3, a member of the paired class homeodomain family of transcription factors and an essential protein for early skeletal muscle development, was shown to be phosphorylated in proliferating mouse primary myoblasts. Furthermore, Ser205, Ser201 and Ser209 were identified as the only sites of phosphorylation on Pax3 in proliferating mouse primary myoblasts. Phosphorylation of Ser205 was shown to be required for the efficient phosphorylation of Ser201 and/or Ser209. Site-specific antibodies were made to each of these three sites when phosphorylated. These three sites are also present and phosphorylated in the Pax3-FOXO1 fusion protein, and phosphorylation of these sites may play a role in ARMS. Thus, these new antibodies may be used in studying the regulation of nerve and muscle development and differentiation and in finding therapeutic solutions for certain disorders, including Waardenburg syndrome and childhood solid muscle tumor alveolar rhabdomyosarcoma (ARMS).
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: November 6, 2012
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Andrew D. Hollenbach, Patrick J. Miller, Kevin N. Dietz
  • Patent number: 8153773
    Abstract: New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2?-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation during in vitro synthesis of mRNA and that hence are “anti-reverse cap analogs” (ARCAs). The ARCA modification ensures that the S atom is precisely positioned within the active sites of cap-binding proteins in both the translational and decapping machinery. The new S-ARCA analogs are resistant to in vivo decapping enzymes. Some S-ARCAs have a higher affinity for eIF4E than the corresponding analogs not containing a phosphorothioate group. When mRNAs containing the various S-ARCAs are introduced into cultured cells, some are translated as much as five-fold more efficiently than mRNAs synthesized with the conventional analog m7GpppG.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: April 10, 2012
    Assignees: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, University of Warsaw
    Inventors: Jacek Jemielity, Ewa M. Grudzien-Nogalska, Joanna Kowalska, Edward Darzynkiewicz, Robert E. Rhoads
  • Patent number: 8147820
    Abstract: An attenuated bacteria has been made by an insertion mutation in the iglC gene of Francisella asiatica, by allelic exchange. The attenuated strain proved to be an effective vaccine by providing protection against an infection of F. asiatica in tilapia, and is believed would at least partially immunize fish from other species of Francisella. The vaccine of the attenuated Francisella asiatica ?iglC mutant can also serve as vectors to present antigens from other pathogens to the fish, thereby serving as vaccines against other pathogens as well. In addition, a highly sensitive and specific assay that can be used for the specific identification of F. asiatica in fish has been developed.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: April 3, 2012
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: John Hawke, Esteban Soto
  • Patent number: 8012517
    Abstract: Noni juice and a protein-free, alcohol precipitate of Noni juice inhibited angiogenesis in in vitro human angiogenesis models. When growth medium contained Noni juice at least over the range from about 2.5% to about 33% (by volume), angiogenesis was blocked. Moreover, Noni juice and an ethanol precipitate were able to destroy a pre-existing angiogenic response as well as prevent the development of new vessels. Noni juice was effective in inhibiting the growth of angiogenic vessels from breast cancer explants. It will also be effective in treating cancers and non-cancerous diseases whose response includes an increase in angiogenesis, e.g., retinopathy of prematurity, neovascular glaucoma, diabetic retinopathy, and psoriasis. The primary antiangiogenic component is believed to be a carbohydrate with a molecular weight less than about 6000 Daltons. In an initial experiment, oral administration of Noni juice appeared to adversely affect the antioangiogenic component(s) in the juice.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: September 6, 2011
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Eugene A. Woltering, Conrad A. Hornick, Amy E. Myers
  • Patent number: 7960173
    Abstract: Isolation and amplification of cardiac pacemaking/conduction system cells and development of a pacemaking/conduction system in vitro using the expression of surrogate expression markers. Use of markers to identify and select for clusters of pacemaking “nodes” that are functionally coupled with adjacent contracting regions and generation of cell populations displaying electrical properties characteristic of specialized pacemaking/conducting cardiac myocytes for modeling the cardiac conduction system, testing of pharmaceuticals and for transplantation.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: June 14, 2011
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Steven M. White, William C. Claycomb
  • Patent number: 7949387
    Abstract: A new method was discovered to analyze continuous spectral curves to determine relative hemoglobin oxygen saturation, using spectral curves collected from a continuous range of wavelengths from about 530 nm to about 584 nm, including spectra from transmitted or reflected light. Using isosbestic points and curve areas, a relative saturation index was calculated. With this method, noninvasive, in vivo measurement of relative oxygen saturation was made using light reflected from blood vessels in the eye and to map and measure relative changes in hemoglobin oxygen saturation in primate retinal vessels and optic nerve head in response to controlled changes in inspired oxygen and intraocular pressure (IOP). This method could also measure oxygen saturation from other blood vessels that reflect light sufficient to give a clear spectra from the blood hemoglobin. Changes in blood oxygen saturation can be monitored with this method for early detection of disease.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: May 24, 2011
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Bahram Khoobehi, James M. Beach
  • Patent number: 7943576
    Abstract: It has been discovered that enterostatin inhibits angiogenesis in an in vitro adipose tissue angiogenesis model. In concentrations from about 10?6 to about 10?9 M, enterostatin effectively blocked the angiogenic response. Enterostatin will be effective in treating noncancerous and cancerous diseases that involve an increase in angiogenesis, e.g., rheumatoid arthritis, retinopathy of prematurity, neovascular glaucoma, diabetic retinopathy, and psoriasis. This, antiangiogenic activity was confirmed in two additional tissue cells lines (liver and neuronal cells) using a microarray analysis.
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: May 17, 2011
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: David A. York, Mie Jung Park
  • Patent number: 7942943
    Abstract: A down-draft fixed bed gasifier is disclosed that produced clean producer or synthesis gas. The gasifier can be installed at a stationary location or can be scaled down to enable placing the gasifier on a trailer that can be moved to the site of biomass generation. The gasifier is vertically oriented and generally cylindrical, and the design allows for a continual input of feedstock into the gasifier with less clogging and without lowering the gas pressure inside the gasifier. The design incorporates an internal catalyst to clean tars from the produced gas, and uses heat from the combustion chamber of the gasifier to heat the catalyst. The flow of air may be either positive flow or negative flow.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: May 17, 2011
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventor: Chandra S. Theegala
  • Patent number: 7943804
    Abstract: The use of ozonation has been discovered to increase the lutein extraction from aflatoxin-free corn and for some batches of alfalfa. In addition, the ozonation will substantially decrease any aflatoxin in the plant source. The structure of lutein as indicated by HPLC elution profile and the function of lutein using an antimutagenic activity was shown not to be affected by the ozonation.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: May 17, 2011
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Joan M. King, Yu Wang
  • Patent number: 7906498
    Abstract: Topical application of cholesterol has been found to be effective in preventing, treating or ameliorating the damage to the cornea caused by Streptococcus pneumoniae. Topical administration of cholesterol caused a significant decrease in the inflammation of the eye. In addition, cholesterol was surprisingly found to be a bactericide to Streptococcus pneumoniae outside the cornea. The effect of cholesterol can be enhanced by further administering a steroid or an antibiotic to the cornea.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: March 15, 2011
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Mary E. Marquart, Richard J. O'Callaghan
  • Patent number: 7879572
    Abstract: It has been discovered that the ability of analogues to affect binding of a labeled ?-casomorphin (an enterostatin antagonist) to recombinant rat F1-ATPase ?-subunit was closely correlated with their enterostatin-like biological activity. Using immunohistochemistry and western blots, the presence of the F1-ATPase ?-subunit was demonstrated in plasma membranes of liver, pancreas and amygdala. The effects of enterostatin on the intracellular localization of the proteins were studied using deconvolution or confocal microscopy. Enterostatin did not alter the location of F1-ATPase a-subunit-RFP but induced movement of the F1-ATPase ?-subunit-GFP to the periphery of cells.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: February 1, 2011
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: David A. York, MieJung Park
  • Patent number: 7772212
    Abstract: Isomaltooligosaccharides (IMOs) produced by Leuconostoc mesenteroides ATCC 13146 fermentation with a sucrose:maltose ratio of 2:1 have been discovered to be effective prebiotics in mixed cultures of microbial populations, including cultures from chicken ceca. Surprisingly in mixed microbial cultures this IMO composition proved as effective as FOS. Thus, these IMOs can be used as effective prebiotics for both birds and mammals. Moreover, the IMOs were discovered to be effective non-competitive inhibitors of ?-glucosidase. These IMOs also will be useful, as an ?-glucosidase inhibitor, in a therapeutic application for several diseases, including obesity, diabetes mellitus, pre-diabetes, gastritis, gastric ulcer, duodenal ulcer, caries, cancer, viral disease such as hepatitis B and C, HIV, and AIDS. A diet with 5-20% IMOs was also shown to reduce the abdominal fat tissue in mammals.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: August 10, 2010
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Donal F. Day, Chang-Ho Chung
  • Patent number: 7709031
    Abstract: An extract of Chinese blackberry (Rubus suavissimus) has been found to inhibit angiogenesis, and two active fractions isolated. Gallic acid was shown to be one of the active anti-angiogenic compounds by an in vitro human angiogenesis model. Aqueous extracts from other plants either known or found to have gallic acid were also found to have anti-angiogenic activity. Various derivatives of gallic acid were found to inhibit angiogenesis. The extract from Chinese blackberry also slowed the growth of a pancreatic tumor and of corneal neovascularization in rats. Extracts from pomegranate were shown to inhibit angiogenesis in fat tissue. Extracts from Rubus spp, and other plants with gallic acid, and gallic acid and its derivatives will be useful for treating various diseases associated with neovascularization, including diabetic retinopathy, psoriasis, tumors, obesity, cancer, rheumatoid arthritis, etc.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: May 4, 2010
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Frank L. Greenway, Zhijun Liu, Eugene A. Woltering
  • Patent number: 7709460
    Abstract: A method and medical composition for the treatment and/or prevention of a functional Vitamin B12 deficiency in an individual that is brought about as a consequence of oxidative stress on biochemical pathways. The functional Vitamin B12 deficiency may eventually present as dementia, other neuropsychiatric abnormality and/or vascular disease. The method involves the administration of a medical composition that supplies a cobalt-sulphur bond in the upper ?-ligand of an intracellular cobalamin molecule thereby facilitating intracellular processing of cobalamin. The cobalt-sulphur bond may be provided directly by administration of a thiolatocobalamin, such as glutathionyl-cobalamin or indirectly by the co-administration of Vitamin B12 (or a derivative thereof) with a sulphur-containing molecule, such as glutathione or a precursor thereof.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: May 4, 2010
    Assignee: Cobalz Limited
    Inventor: Andrew McCaddon
  • Patent number: 7700327
    Abstract: A method has been discovered to produce a resistant starch product that retains the same cooking quality as found in untreated rice starch or flour, but has a higher percentage of starch resistant to ?-amylase digestion. This method uses a debranching enzyme, e.g., pullulanase, to digest the starch, but does not require pre-treating the starch source prior to enzymatic treatment. This method produced resistant starch from low amylose starches, rice starch (24%) and rice flour (20%). Surprisingly the resistant starch product formed by this method retained the pasting characteristics of the untreated flour or starch, and was heat stable. This method may also be used to produce resistant starch from other botanical sources, e.g., corn, wheat, potato, oat, barley, tapioca, sago, and arrowroot. Resistant starch produced by this method has a variety of uses in food products.
    Type: Grant
    Filed: September 7, 2004
    Date of Patent: April 20, 2010
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Joan M. King, Siow Ying Tan
  • Patent number: 7585387
    Abstract: An oxidative solution (Ox-B, a solution of no less than 5:1 sodium hypochlorite: hydrogen peroxide) was found to remove both lignin and hemicellulose from sugarcane bagasse. After treatment the cellulosic residue readily separated from the lignin and hemicellulose by sedimentation. The residue (the pulp) contained up to 80% by weight cellulose, and was easily degradable by cellulase enzyme. A treatment of oxidation with low concentrations of Ox-B, followed by a caustic wash, produced a cellulose residue that was able to be almost completely hydrolyzed to simple sugars by cellulase. Due to the low amount chemical used and the efficiency of the degradation, this process has commercial potential.
    Type: Grant
    Filed: March 8, 2006
    Date of Patent: September 8, 2009
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Donal F. Day, Chang-Ho Chung
  • Patent number: 7563306
    Abstract: An apparatus and method of conditioning humidity and temperature in the process air stream of a desiccant dehumidifier used to dry moisture-laden spaces and structures by replacing moisture-laden air with dehumidified air to increase the rate of water evaporation within the affected areas. An air-dehumidifier comprises a dehumidification assembly having a desiccant rotor assembly, a shielded radiant burner assembly, and a control system. The shielded radiant burner assembly is used to regenerate the desiccant rotor by removing moisture from the reactivation quadrant, where high velocity (at least 500 ft/min) air streams are often flowed, by projecting radiant heat onto the rotor, while minimizing the potential for the high velocity air streams interrupting the combustion of air and fuel in the radiant burner.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: July 21, 2009
    Assignee: Technologies Holdings Corporation
    Inventors: Charles A. Boutall, Albert Keith Teakell
  • Patent number: 7427662
    Abstract: Apolipoprotein A-I-rich Lhigh-density Lipoprotein 2 (HDL2) and Apolipoprotein A-I (ApoA-I) was discovered to inhibit angiogenesis in an in vitro human angiogenesis model, the human placental vein angiogenesis model. Apolipoprotein A-I was able to destroy a pre-existing angiogenic response as well as prevent the development of new vessels. Application of Apolipoprotein A-I will be effective in inhibiting tumor growth dependent on angiogenesis, and in decreasing existing blood vessels formed by tumors. It will also be effective in treating non-cancerous diseases which symptoms include an increase in angiogenesis, e.g., psoriasis, retinopathy of prematurity, neovascular glaucoma, diabetic retinopathy, obesity, and psoriasis.
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: September 23, 2008
    Assignee: Baord of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Conrad A. Hornick, Eugene A. Woltering